<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343004</url>
  </required_header>
  <id_info>
    <org_study_id>BA058-05-003</org_study_id>
    <secondary_id>ACTIVE Trial</secondary_id>
    <nct_id>NCT01343004</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women</brief_title>
  <acronym>ACTIVE</acronym>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Comparative Multicenter Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women With Severe Osteoporosis and at Risk of Fracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radius Health, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether BA058 (abaloparatide), a parathyroid
      hormone-related peptide, is effective in preventing fractures in postmenopausal women with
      severe osteoporosis who are at risk of fractures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, comparative Phase 3, multicenter
      international study to evaluate the efficacy and safety of BA058 (abaloparatide) 80 µg in the
      prevention of fracture in otherwise healthy ambulatory postmenopausal women with severe
      osteoporosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With New Vertebral Fractures at 18 Months</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 18 Months</measure>
    <time_frame>Basline and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) of Total Hip From Baseline to Month 18</measure>
    <time_frame>Baseline and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) of Femoral Neck From Baseline to Month 18</measure>
    <time_frame>Baseline and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-vertebral Fractures at 18 Months</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment-Emergent Adverse Events Associated With Hypercalcemia at 18 Months</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2463</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo identical in appearance to BA058 study drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA058 80 mcg (abaloparatide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>teriparatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blinded until after randomization, then open-label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 0 mcg subcutaneous daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BA058 80 mcg</intervention_name>
    <description>BA058 80 mcg subcutaneous daily</description>
    <arm_group_label>BA058 80 mcg (abaloparatide)</arm_group_label>
    <other_name>abaloparatide, Abaloparatide-SC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teriparatide</intervention_name>
    <description>teriparatide 20 mcg subcutaneous daily</description>
    <arm_group_label>teriparatide</arm_group_label>
    <other_name>Forteo</other_name>
    <other_name>Forsteo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy ambulatory postmenopausal (≥ 5 years) women from 50 to 85 years of age
             (inclusive) with a diagnosis of osteoporosis

          -  The women are to have a bone mineral density (BMD) T score ≤ -2.5 and &gt; -5.0 at the
             lumbar spine or hip (femoral neck) by dual energy x-ray absorptiometry (DXA) and
             radiological evidence of 2 or more mild or one or more moderate lumbar or thoracic
             vertebral fractures, or history of low trauma forearm, humerus, sacral, pelvic, hip,
             femoral, or tibial fracture within the past 5 years. Postmenopausal women older than
             65 who meet the above fracture criteria but have a T score ≤ -2.0 and &gt; -5.0 may be
             enrolled. Women older than 65 who do not meet the fracture criteria may also be
             enrolled if their T score is ≤ -3.0 and &gt; -5.0

          -  Normal physical exam, vital signs, electrocardiogram (ECG) and medical history

          -  Laboratory tests within the normal range including serum calcium, PTH(1-84), serum
             phosphorus and alkaline phosphatase

        Exclusion Criteria:

          -  History of more than 4 mild or moderate spine fractures or any severe fracture

          -  Abnormality of the spine or hip that would prohibit assessment of bone mineral density
             (BMD)

          -  Unexplained elevation of serum alkaline phosphatase, history of bone disorders (such
             as Paget's disease) or a diagnosis of cancer within the last 5 years (with the
             exception of basal cell or squamous cancer of the skin)

          -  History of thyroid, parathyroid, or adrenal disorders, or malabsorptive syndromes or
             any chronic or recurrent diseases or disturbances that would interfere with the
             interpretation of study data or compromise the safety of the patient

          -  Prior treatment with parathyroid hormone (PTH) or parathyroid hormone-related peptid
             (PTHrP)

          -  Prior treatment with bisphosphonates, fluoride, or strontium within the past five
             years or treatment with androgens, anabolic steroids, corticosteroids or selective
             estrogen receptor modulators within the past 12 months (except hormone replacement
             therapy)

          -  Prior treatment with an investigational drug within the past 12 months

          -  History of nephrolithiasis or urolithiasis within the past five years, or history of
             osteosarcoma at any time
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Radius Health, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Radius Health, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>N. Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasilia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paolo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vitoria</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ballerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zgierz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Hong Kong</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>April 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2011</study_first_posted>
  <results_first_submitted>October 25, 2016</results_first_submitted>
  <results_first_submitted_qc>January 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2017</results_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BA058</keyword>
  <keyword>abaloparatide</keyword>
  <keyword>Abaloparatide-SC</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>postmenopausal</keyword>
  <keyword>bone loss</keyword>
  <keyword>ACTIVE</keyword>
  <keyword>fracture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo identical in appearance to BA058 study drug
Placebo: Placebo 0 mcg subcutaneous daily</description>
        </group>
        <group group_id="P2">
          <title>BA058 80 mcg (Abaloparatide)</title>
          <description>BA058 80 mcg: BA058 80 mcg subcutaneous daily</description>
        </group>
        <group group_id="P3">
          <title>Teriparatide</title>
          <description>Blinded until after randomization, then open-label
teriparatide: teriparatide 20 mcg subcutaneous daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="821"/>
                <participants group_id="P2" count="824"/>
                <participants group_id="P3" count="818"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="637"/>
                <participants group_id="P2" count="606"/>
                <participants group_id="P3" count="658"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
                <participants group_id="P2" count="218"/>
                <participants group_id="P3" count="160"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) Population included all patients who were randomized into the study by assigning the randomized study medication kit on Day 1.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo identical in appearance to BA058 study drug
Placebo: Placebo 0 mcg subcutaneous daily</description>
        </group>
        <group group_id="B2">
          <title>BA058 80 mcg (Abaloparatide)</title>
          <description>BA058 80 mcg: BA058 80 mcg subcutaneous daily</description>
        </group>
        <group group_id="B3">
          <title>Teriparatide</title>
          <description>Blinded until after randomization, then open-label
teriparatide: teriparatide 20 mcg subcutaneous daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="821"/>
            <count group_id="B2" value="824"/>
            <count group_id="B3" value="818"/>
            <count group_id="B4" value="2463"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.7" spread="6.5"/>
                    <measurement group_id="B2" value="68.9" spread="6.5"/>
                    <measurement group_id="B3" value="68.8" spread="6.6"/>
                    <measurement group_id="B4" value="68.8" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="821"/>
                    <measurement group_id="B2" value="824"/>
                    <measurement group_id="B3" value="818"/>
                    <measurement group_id="B4" value="2463"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With New Vertebral Fractures at 18 Months</title>
        <time_frame>18 months</time_frame>
        <population>Modified intent-to-treat (MITT) population included all patients with pre-treatment and end-of-treatment evaluable radiologic assessment (spine X-ray).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo identical in appearance to BA058 study drug
Placebo: Placebo 0 mcg subcutaneous daily</description>
          </group>
          <group group_id="O2">
            <title>BA058 80 mcg (Abaloparatide)</title>
            <description>BA058 80 mcg: BA058 80 mcg subcutaneous daily</description>
          </group>
          <group group_id="O3">
            <title>Teriparatide</title>
            <description>Blinded until after randomization, then open-label
teriparatide: teriparatide 20 mcg subcutaneous daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Vertebral Fractures at 18 Months</title>
          <population>Modified intent-to-treat (MITT) population included all patients with pre-treatment and end-of-treatment evaluable radiologic assessment (spine X-ray).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="711"/>
                <count group_id="O2" value="690"/>
                <count group_id="O3" value="717"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 18 Months</title>
        <time_frame>Basline and 18 months</time_frame>
        <population>Intent-to-treat population included all patients who were randomized into the study by assigning the randomized study medication kit on Day 1. Baseline BMD data were missing for some patients; the method of last observation carried forward (LOCF) was used to impute missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo identical in appearance to BA058 study drug
Placebo: Placebo 0 mcg subcutaneous daily</description>
          </group>
          <group group_id="O2">
            <title>BA058 80 mcg (Abaloparatide)</title>
            <description>BA058 80 mcg: BA058 80 mcg subcutaneous daily</description>
          </group>
          <group group_id="O3">
            <title>Teriparatide</title>
            <description>Blinded until after randomization, then open-label
teriparatide: teriparatide 20 mcg subcutaneous daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 18 Months</title>
          <population>Intent-to-treat population included all patients who were randomized into the study by assigning the randomized study medication kit on Day 1. Baseline BMD data were missing for some patients; the method of last observation carried forward (LOCF) was used to impute missing data.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="821"/>
                <count group_id="O2" value="823"/>
                <count group_id="O3" value="818"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="3.82"/>
                    <measurement group_id="O2" value="9.20" spread="7.54"/>
                    <measurement group_id="O3" value="9.12" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were derived from contrast tests based on the ANCOVA model fitted using only the data of the two treatment groups to be compared.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were derived from contrast tests based on the ANCOVA model fitted using only the data of the two treatment groups to be compared.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8155</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were derived from contrast tests based on the ANCOVA model fitted using only the data of the two treatment groups to be compared.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) of Total Hip From Baseline to Month 18</title>
        <time_frame>Baseline and 18 months</time_frame>
        <population>Intent-to-treat population included all patients who were randomized into the study by assigning the randomized study medication kit on Day 1. Baseline BMD data were missing for some patients; the method of last observation carried forward (LOCF) was used to impute missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo identical in appearance to BA058 study drug
Placebo: Placebo 0 mcg subcutaneous daily</description>
          </group>
          <group group_id="O2">
            <title>BA058 80 mcg (Abaloparatide)</title>
            <description>BA058 80 mcg: BA058 80 mcg subcutaneous daily</description>
          </group>
          <group group_id="O3">
            <title>Teriparatide</title>
            <description>Blinded until after randomization, then open-label
teriparatide: teriparatide 20 mcg subcutaneous daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) of Total Hip From Baseline to Month 18</title>
          <population>Intent-to-treat population included all patients who were randomized into the study by assigning the randomized study medication kit on Day 1. Baseline BMD data were missing for some patients; the method of last observation carried forward (LOCF) was used to impute missing data.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="820"/>
                <count group_id="O2" value="822"/>
                <count group_id="O3" value="818"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="2.77"/>
                    <measurement group_id="O2" value="3.44" spread="3.51"/>
                    <measurement group_id="O3" value="2.81" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were derived from contrast tests based on the ANCOVA model fitted using only the data of the two treatment groups to be compared.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were derived from contrast tests based on the ANCOVA model fitted using only the data of the two treatment groups to be compared.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were derived from contrast tests based on the ANCOVA model fitted using only the data of the two treatment groups to be compared.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) of Femoral Neck From Baseline to Month 18</title>
        <time_frame>Baseline and 18 months</time_frame>
        <population>Intent-to-treat population included all patients who were randomized into the study by assigning the randomized study medication kit on Day 1. Baseline BMD data were missing for some patients; the method of last observation carried forward (LOCF) was used to impute missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo identical in appearance to BA058 study drug
Placebo: Placebo 0 mcg subcutaneous daily</description>
          </group>
          <group group_id="O2">
            <title>BA058 80 mcg (Abaloparatide)</title>
            <description>BA058 80 mcg: BA058 80 mcg subcutaneous daily</description>
          </group>
          <group group_id="O3">
            <title>Teriparatide</title>
            <description>Blinded until after randomization, then open-label
teriparatide: teriparatide 20 mcg subcutaneous daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) of Femoral Neck From Baseline to Month 18</title>
          <population>Intent-to-treat population included all patients who were randomized into the study by assigning the randomized study medication kit on Day 1. Baseline BMD data were missing for some patients; the method of last observation carried forward (LOCF) was used to impute missing data.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="820"/>
                <count group_id="O2" value="822"/>
                <count group_id="O3" value="818"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="3.57"/>
                    <measurement group_id="O2" value="2.90" spread="4.21"/>
                    <measurement group_id="O3" value="2.26" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were derived from contrast tests based on the ANCOVA model fitted using only the data of the two treatment groups to be compared.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were derived from contrast tests based on the ANCOVA model fitted using only the data of the two treatment groups to be compared.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <method_desc>P-values were derived from contrast tests based on the ANCOVA model fitted using only the data of the two treatment groups to be compared.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-vertebral Fractures at 18 Months</title>
        <time_frame>18 months</time_frame>
        <population>Intent-to-treat population included all patients who were randomized into the study by assigning the randomized study medication kit on Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo identical in appearance to BA058 study drug
Placebo: Placebo 0 mcg subcutaneous daily</description>
          </group>
          <group group_id="O2">
            <title>BA058 80 mcg (Abaloparatide)</title>
            <description>BA058 80 mcg: BA058 80 mcg subcutaneous daily</description>
          </group>
          <group group_id="O3">
            <title>Teriparatide</title>
            <description>Blinded until after randomization, then open-label
teriparatide: teriparatide 20 mcg subcutaneous daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-vertebral Fractures at 18 Months</title>
          <population>Intent-to-treat population included all patients who were randomized into the study by assigning the randomized study medication kit on Day 1.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="821"/>
                <count group_id="O2" value="824"/>
                <count group_id="O3" value="818"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0318</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2304</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3361</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treatment-Emergent Adverse Events Associated With Hypercalcemia at 18 Months</title>
        <time_frame>18 months</time_frame>
        <population>Safety population included all patients who received 1 or more doses of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo identical in appearance to BA058 study drug
Placebo: Placebo 0 mcg subcutaneous daily</description>
          </group>
          <group group_id="O2">
            <title>BA058 80 mcg (Abaloparatide)</title>
            <description>BA058 80 mcg: BA058 80 mcg subcutaneous daily</description>
          </group>
          <group group_id="O3">
            <title>Teriparatide</title>
            <description>Blinded until after randomization, then open-label
teriparatide: teriparatide 20 mcg subcutaneous daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment-Emergent Adverse Events Associated With Hypercalcemia at 18 Months</title>
          <population>Safety population included all patients who received 1 or more doses of study medication</population>
          <units>Hypercalcemic events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="820"/>
                <count group_id="O2" value="822"/>
                <count group_id="O3" value="818"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo identical in appearance to BA058 study drug
Placebo: Placebo 0 mcg subcutaneous daily</description>
        </group>
        <group group_id="E2">
          <title>BA058 80 mcg (Abaloparatide)</title>
          <description>BA058 80 mcg: BA058 80 mcg subcutaneous daily</description>
        </group>
        <group group_id="E3">
          <title>Teriparatide</title>
          <description>Blinded until after randomization, then open-label
teriparatide: teriparatide 20 mcg subcutaneous daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Myocardial infraction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Thyroid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Malculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Retinal artery occulusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Change of bowel habit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Enterocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Bronchoscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Lumbar spine stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Spondylisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Breast cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Angiolipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Bile duct adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Chronic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Myeloproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Subarchnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Allergic bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermititis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Colporrhaphy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Joint arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Osteosynthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Rectocele repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Removal of internal fixation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Toe operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="447" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="492" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="456" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="818"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalciuria</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="820"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="822"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="818"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Results may not be published prior to the Study Report completion. Investigators may publish results, providing a manuscript to the Sponsor =/&gt; 30 days prior to its submission to a publisher. Sponsor will provide manuscript to Investigators =/&gt; 30 days prior to its submission. Investigator shall comply with Sponsor's policy, withholding publication for an additional 60 days to permit the Sponsor to obtain patent or other proprietary rights protection, if deemed necessary.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Program Director</name_or_title>
      <organization>Radius Health, Inc.</organization>
      <phone>(617) 551-4700</phone>
      <email>info@radiuspharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

